|Home | About | Journals | Submit | Contact Us | Français|
This study investigates the prevalence and demographic characteristics of hypersexuality in Parkinson’s disease (PD). Impulse control disorders in PD patients have been associated with dopamine agonist therapy. Moreover, hypersexuality and pathological gambling have been associated with males, while females may be inherently thought to be more likely to participate in compulsive shopping and binge-eating behaviors. In this study, a screening mail-in survey was sent to all PD patients at a single Movement Disorders Center. One hundred forty one of 400 (35.3%) research packets were returned completed. Fifteen of 141 patients met initial screening criteria for hypersexual behavior. After detailed interview, only 6/141 (4.3%) of PD patients met criteria for pathologic hypersexual behavior. These behaviors included: compulsive masturbation, prostitution, and paraphilias. Patients with a younger age of PD onset were more likely to exhibit hypersexual behavior. Unlike previous report, no significant association was found between hypersexuality and gender or dopamine agonist use. Rather, this study suggests that physicians should be vigilant for hypersexual behavior in all PD patients, regardless of gender and PD medication regimen. Ultimately, given the innate sensitivity of the topic and survey limitations, it is very likely that hypersexual behavior in our cohort, as it is in the general PD population, has been under-reported.
Impulse control disorders are increasingly reported in Parkinson’s disease (PD). Examples of these iatrogenic behaviors seen in PD include: binge eating, excessive spending, compulsive shopping, pathological gambling, and hypersexuality.1 Hypersexuality in particular is a psychiatric issue that patients are often reluctant to discuss. Voon and colleagues found the lifetime prevalence of pathologic hypersexuality in PD to be 2.4%.1 Hypersexual behavior typically entails an increase in premorbid sexual activities as well as an increase in the variety of sexual behaviors.2 While no direct cause has been identified, Voon and colleagues found hypersexuality to be significantly associated with male sex and an earlier age of PD onset.1 Treatment with dopamine agonist therapy and a history of impulse control disorders has also been proposed as possible risk factors.3
This study investigates prevalence and demographic characteristics of hypersexual behavior in PD patients residing in north central Florida, USA.
The study was approved by the Institutional Review Board of the University of Florida. Four hundred packets were mailed to all patients diagnosed with idiopathic PD enrolled in the Movement Disorders Center of the University of Florida. The diagnosis was made by a fellowship trained movement disorders specialists and was based on fulfilling strict United Kingdom Brain Bank Criteria.4 As approved by the University of Florida Institutional Review Board, in the survey phase of this study, the subject’s response to the questionnaire was considered an “implied consent”. In addition, all patients signed a separate informed consent to allow us to contact them, if needed, and to have their data analyzed. Information on demographics, health history, current therapies, and hypersexual behavior was obtained in addition to the Neuropsychological Inventory (NPI) and Beck’s Depression Inventory (BDI).
Patients were asked directly if they participated in hypersexual behavior on the hypersexual behavior questionnaire (see Table 1). As part of the mail-in survey, the patients were asked if they would like to be further contacted in regard to this research survey. Only those patients who consented were subsequently interviewed for confirmation and classification to determine if they met the diagnostic criteria for subsybdromal or pathological hypersexuality as outlined by Voon and colleagues (see Table 2).1 The patient’s significant other participated in the interview if the patient consented and was available at the time.
Continuous demographic variables (eg, age of onset, PD duration, NPI, BDI) were analyzed using unpaired t tests. Categorical demographic variables (eg, gender, handedness, marital status, times married, side of PD onset, smoking history, psychiatric history, family psychiatric history, dopamine agonist therapy, and levodopa therapy) were analyzed using Fisher’s exact tests and Chi-squared tests. All statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA) software.
One hundred forty-one from 400 (35.3%) patients returned completed research packets. This sample had a mean age of 68.0 years (± 10.2 yrs) and an average PD duration of 6.7 years (± 5.9 yrs). Fifteen of 141 respondents self-identified as possessing hypersexual behavior. Only six of 15 patients met criteria for pathological hypersexuality (n = 5) or subsyndromal hypersexuality (n = 1). Whenever there was a question on the veracity of patient reports or reliability of their testimony, the subject’s partner participated in the interviews, and in all cases these patients qualified as exhibiting pathological hypersexual behavior. The prevalence therefore of hypersexuality in our cohort was 4.3% (6/141). In these six patients, the most common hypersexual behavior reported was increased pornography interest (magazine, video, or Internet) (three of the six patients), and compulsive masturbation (two patients). Individually, patients also reported novel interests in a wide range of behaviors including sexual toys, sadomasochism, prostitution, and cross-dressing. The average age of PD onset was significantly lower in the hypersexual group (50.2 yrs ± 3.0) compared to the nonhypersexual group (61.5 yrs ± 1.0) (t(124) = 2.437; p < 0.05). No significant association was found between hypersexual behavior and gender, handedness, marital status, times married, side of PD onset, psychiatric history, family psychiatric history, dopamine agonist therapy, levodopa therapy, PD duration, NPI or BDI score. Interestingly, this sample showed a significant association between a history of smoking and not developing hypersexual behavior (Fisher’s exact test p < 0.05).
Given the innate sensitivity of the topic, it is very likely that hypersexual behavior is under-reported. Despite the limitations (and probable underestimation) of a mail-in survey, the prevalence of hypersexuality in our PD cohort (4.3%) was slightly higher than the 2.4% reported by Voon and colleagues.1 Patients with a younger age of PD onset were more likely to exhibit hypersexual behavior.
Previously, hypersexuality was associated with males but not females.1 Our current study failed to substantiate this finding. This highlights the possibility of hypersexual behavior in female patients that may be missed due to the inherently small sample size of hypersexual patients.
Although the association between younger age of onset and hypersexual behavior might be thought to be due to a greater use of dopamine agonist therapy in these patients, no significant relationship was found between dopamine agonist therapy and hypersexual behavior in this sample. Klos and colleagues found that hypersexual behavior typically began after eight months of dopamine therapy and then resolved after discontinuing dopamine agonist therapy.5 It should be noted that a few patients in our study did mention a similar experience. Shaw and colleagues proposed dopamine therapy in general may cause hypersexuality both directly, by increasing libido and arousal, and indirectly by interacting with reward-center neural substrates.2 This is in line with the Voon and colleagues finding that a higher total levodopa dose equivalent, but not dopamine agonist dose, was associated with hypersexuality.1 Intuitively, it seems very likely that manipulation of the dopamine system would result in changes in reward-seeking behavior. Additional compulsive behaviors coincide with hypersexuality in up to 60% of hypersexual PD patients.5
Given that only a relatively small percentage of PD patients exhibit hypersexuality or any type of impulse control disorder, it seems likely that susceptibility may be due to underlying heritable temperamental traits such as novelty-seeking.6 Moreover, Pontone and colleagues found an association between impulse control disorders and depressed mood, disinhibition, irritability, and appetite disturbance.7 Table 3 shows demographic data from our current hypersexual population. While not statistically significant, five out of six patients had either a personal or family history of previous psychiatric disorders. Notably, none of the patients had a history of hypersexual behavior prior to PD onset. Also, there appears to be a trend of elevated depression scores, as measured by the BDI, in a majority of these patients.
It should be noted that this study relied on a population of patients all from a single Movement Disorders Center. Therefore it is possible that it does not represent the general PD population. Similar studies in subsequent populations would help to eliminate the possibility of a population bias.
Also, due to survey limitations, as well as possible patient cognitive decline, it is possible that not all patients understood the survey questions as intended. Since we relied on initial self-identification of hypersexual behavior before interviewing, it is quite possible that not all patients were able or willing to make this identification. In the future, studies with a larger hypersexual sample size might serve to verify significant demographic variables.
Our study suggests that hypersexuality may be more prevalent than currently realized. It confirms previous reports that it occurs more commonly in the younger PD age group. Clinicians should be aware of possible hypersexual behavior in both sexes, regardless of dopamine agonist therapy, and be prepared to provide information and support to their patients and their patients’ caregivers.
This study was funded in part by a National Parkinson’s Foundation Center of Excellence Research Grant as well as a summer research grant funded by the Medical Sciences Research Program at the University of Florida College of Medicine.